case_images: PMC10838969_01
case_images: The patient's clinical course after admission as assessed by the myasthenia gravis-activities of daily living (MG-ADL) scale. The timing of each therapy, the MG-ADL results, and the titer of anti-AChR antibody (anti-AChR Ab) are shown. Day 0: the day of hospital admission. Note that serial assessments of the patient's serum anti-AChR antibody titers paralleled the clinical improvement assessed by the MG-ADL scale after efgartigimod administration. IVIG, intravenous immunoglobulin; IVMP, intravenous methylprednisolone; PE, plasmapheresis; PSL, prednisolone.
case_images: fneur-15-1321058-g001.jpg
case_images: PMC10838969_01_fneur-15-1321058-g001.jpg
case_images: fig1
case_images: After admission (Figures 1, 2), the patient required tube feeding due to severe dysphagia.
case_images: The patient's clinical course after admission as assessed by the myasthenia gravis composite (MGC) scale. Note that the serial assessments of the patient's serum anti-AChR antibody titers paralleled the clinical improvements assessed by the MGC scale after efgartigimod administration.
case_images: fneur-15-1321058-g002.jpg
case_images: PMC10838969_01_fneur-15-1321058-g002.jpg
case_images: fig2
case_images: After admission (Figures 1, 2), the patient required tube feeding due to severe dysphagia.
case_images: The serial data of the IgG concentration and anti-AChR antibody. Note that the serum IgG concentration was decreased after both plasmapheresis and intravenous efgartigimod, whereas anti-AChR antibodies were decreased after the intravenous efgartigimod only.
case_images: fneur-15-1321058-g003.jpg
case_images: PMC10838969_01_fneur-15-1321058-g003.jpg
case_images: fig3
case_images: In addition, her serum IgG concentration was decreased after both plasmapheresis and intravenous efgartigimod, whereas anti-AChR antibodies were decreased after intravenous efgartigimod only (Figure 3).